A novel series of fifteen 3-(3,4-dihydroisoquinolin-2($1H$)-yl)-𝑁-(substituted phenyl) propanamides 3(a-o) were synthesized by reacting the corresponding 3-chloro-𝑁-(aryl) propanamides 2(a-o) with 1,2,3,4-tetrahydroisoquinoline 1 in acetonitrile. The compounds have been characterized on the basis of elemental analysis and spectral data. All the compounds were evaluated for their HIV-1 RT inhibitory activity. Among the synthesized compounds, 3-(3,4-dihydroisoquinolin-2($1H$)-yl)-𝑁-𝑜-tolyl propanamide 3d and 3-(3,4-dihydroisoquinolin-2(1H)-yl)-𝑁-(2,4,6-tribromophenyl)propanamide 3f were identified as significant inhibitors of HIV-1 reverse transcriptase with 56% and 43% residual RT activity respectively at the final concentration of 40 𝜇M when compared with the standard drug Efavirenz. Docking studies with HIV-1 RT (PDB ID 1rt2) were also performed in order to investigate the binding pattern of these compounds.
Volume 135, 2023
Continuous Article Publishing mode
Click here for Editorial Note on CAP Mode